Displaying drugs 6826 - 6850 of 8178 in total
Rotigaptide
Rotigaptide is under investigation for the basic science of Heart Disease and Vascular Disease.
Investigational
Matched Description: … Rotigaptide is under investigation for the basic science of Heart Disease and Vascular Disease. …
Tenalisib
Tenalisib is under investigation in clinical trial NCT03711604 (Compassionate Use Study of Tenalisib (RP6530)).
Investigational
Matched Description: … Tenalisib is under investigation in clinical trial NCT03711604 (Compassionate Use Study of Tenalisib …
TPCA-1
TPCA-1 is a selective inhibitor of human IκB kinase 2 (IKK-2).
Investigational
Matched Description: … TPCA-1 is a selective inhibitor of human IκB kinase 2 (IKK-2).[A253152] …
AQ-13
AQ-13 is an 4-aminoquinoline analog being investigated for the treatment of malaria.
Investigational
Matched Description: … AQ-13 is an 4-aminoquinoline analog being investigated for the treatment of malaria. …
AV-0113
AV-0113 consists of IL-12 secreting dendritic cells loaded with autologous tumor lysate.
Investigational
Matched Description: … AV-0113 consists of IL-12 secreting dendritic cells loaded with autologous tumor lysate. …
Irpagratinib
Irpagratinib (ABSK011) is a highly selective inhibitor of fibroblast growth factor receptor (FGFR) 4.
Investigational
Matched Description: … Irpagratinib (ABSK011) is a highly selective inhibitor of fibroblast growth factor receptor (FGFR) 4. …
Celastrol
Celastrol is a pentacyclic triterpenoid isolated from the root extracts of Tripterygium wilfordii.
Investigational
Matched Description: … Celastrol is a pentacyclic triterpenoid isolated from the root extracts of _Tripterygium wilfordii_. …
ATL1102
ATL1102 is a second-generation antisense inhibitor of CD49d, an immunesystem protein known as VLA-4, an immune cell molecule. It works by entering cells and targeting genes.
Investigational
Matched Description: … ATL1102 is a second-generation antisense inhibitor of CD49d, an immunesystem protein known as VLA-4, …
Laromustine
VNP40101M is a novel alkylating agent that has been used in trials studying the treatment of Leukemia, Lymphoma, Lung Cancer, Small Intestine Cancer, and Myelodysplastic Syndromes, among others.
Investigational
Matched Description: … VNP40101M is a novel alkylating agent that has been used in trials studying the treatment of Leukemia …
Tandamine
Tandamine was researched in 1970s as an antidepressant but was never commercialized. Tandamine is an analog of pirandamine and it acts as a selective serotonin reuptake inhibitor (SSRI).
Experimental
Matched Description: … Tandamine is an analog of pirandamine and it acts as a selective serotonin reuptake inhibitor (SSRI). …
Eleclazine
Eleclazine has been used in trials studying the treatment of LQT2 Syndrome, Long QT Syndrome, Ischemic Heart Disease, Ventricular Arrhythmia, and Long QT Syndrome Type 3, among others.
Investigational
Matched Description: … Eleclazine has been used in trials studying the treatment of LQT2 Syndrome, Long QT Syndrome, Ischemic …
MIP-1095 I-123
123 I Mip 1095 is under investigation in clinical trial NCT00712829 (Study to Evaluate the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of Two Prostate Cancer Imaging Agents).
Investigational
Matched Description: … NCT00712829 (Study to Evaluate the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of …
Nerofe
Nerofe is under investigation in clinical trial NCT03059615 (A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS).
Investigational
Matched Description: … Nerofe is under investigation in clinical trial NCT03059615 (A Phase 2a, Open-Label, Two Stage Study of …
Tavapadon
Tavapadon is under investigation in clinical trial NCT02262767 (A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 Co-administered With Trimethobenzamide Hydrochloride in Healthy Subjects).
Investigational
Matched Description: … in clinical trial NCT02262767 (A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of …
PCS-499
PCS-499 is under investigation in clinical trial NCT01487109 (A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients).
Investigational
Matched Description: … under investigation in clinical trial NCT01487109 (A Phase 2 Study to Evaluate the Safety and Efficacy of …
Ontamalimab
Ontamalimab is under investigation in clinical trial NCT03627091 (Efficacy and Safety Study of SHP647 as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)).
Investigational
Matched Description: … Ontamalimab is under investigation in clinical trial NCT03627091 (Efficacy and Safety Study of SHP647 …
Silmitasertib
Silmitasertib is under investigation in clinical trial NCT03904862 (Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery).
Investigational
Matched Description: … Silmitasertib is under investigation in clinical trial NCT03904862 (Testing the Safety and Tolerability of …
Zampilimab
Zampilimab is under investigation in clinical trial NCT04335578 (A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of UCB7858 in Adult Kidney Transplant Recipients With Chronic Allograft Injury).
Investigational
Matched Description: … clinical trial NCT04335578 (A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of …
Volagidemab
Volagidemab is under investigation in clinical trial NCT03117998 (Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus).
Investigational
Matched Description: … clinical trial NCT03117998 (Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of …
MaxAdFVIII
MaxAdFVIII is an adenoviral vector that expresses the full-length human Factor VIII (hFVIII) cDNA. First developed by GenStar, it is being investigated for the treatment of hemophilia.
Investigational
Matched Description: … First developed by GenStar, it is being investigated for the treatment of hemophilia. …
RLYB212
RLYB212 is a human monoclonal antibody against Antigen-1A Immunoglobulin (HPA-1A). It is currently being developed by Rallybio for the prevention of fetal and neonatal alloimmune thrombocytopenia.
Investigational
Matched Description: … It is currently being developed by Rallybio for the prevention of fetal and neonatal alloimmune thrombocytopenia …
Bacteroides thetaiotaomicron
Bacteroides thetaiotaomicron is a live biotherapeutic. Developed by 4D Pharma, Thetanix, an oral formulation comprising lyophilized Bacteroides thetaiotaomicron, is being investigated for the treatment of Crohn’s disease.
Investigational
Matched Description: … formulation comprising lyophilized Bacteroides thetaiotaomicron, is being investigated for the treatment of …
Ispectamab debotansine
Ispectamab debotansine is an antibody drug conjugate comprised of an anti-B cell maturation (BCMA) IgG1 humanized antibody conjugated covalently to the dibenzocyclooctyne (DBCO) noncleavable linker maytansinoid warhead.
Investigational
Matched Description: … Ispectamab debotansine is an antibody drug conjugate comprised of an anti-B cell maturation (BCMA) IgG1 …
LMB-100
LMB-100 is a is an antibody-toxin conjugate with an antimesothelin Fab linked to a 24-kilodalton portion of Pseudomonas exotoxin A with mutations that decrease immunogenicity.
Investigational
Matched Description: … 100 is a is an antibody-toxin conjugate with an antimesothelin Fab linked to a 24-kilodalton portion of …
Visugromab
Visugromab is under investigation in clinical trial NCT06059547 (Neoadjuvant Immunotherapy in Combination With the Anti-gdf-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer).
Investigational
Matched Description: … Neoadjuvant Immunotherapy in Combination With the Anti-gdf-15 Antibody Visugromab (CTL-002) for Treatment of …
Displaying drugs 6826 - 6850 of 8178 in total